News & Updates

Show Multimedia Only

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

22 Oct 2025 by

Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

22 Oct 2025

CORE model outperforms FIB-4 in predicting liver-related outcomes

22 Oct 2025 by

A novel risk score, named Cirrhosis Outcome Risk Estimator (CORE), performs better than FIB-4 in predicting liver-related outcomes in the general population, a study has shown. This model is based on a flexible modelling approach and utilizes biomarkers that are easily accessible in primary care.

CORE model outperforms FIB-4 in predicting liver-related outcomes

22 Oct 2025

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

22 Oct 2025 by

In the phase III C-POST trial, adjuvant cemiplimab prolongs disease-free survival (DFS) in individuals at high risk for recurrence of cutaneous squamous cell carcinoma (cSCC).

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

22 Oct 2025

Even low alcohol intake detrimental to East Asian men with MASLD

22 Oct 2025

Intake of even small amounts of alcohol appears to pose a significant health risk for East Asian men with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a South Korean nationwide cohort study.

Even low alcohol intake detrimental to East Asian men with MASLD

22 Oct 2025

Prehabilitation improves surgical outcomes for patients with sarcopenia

21 Oct 2025

A prehabilitation program that integrates exercise and nutritional interventions helps reduce postoperative morbidity in patients with sarcopenia undergoing major liver resection, according to a study.

Prehabilitation improves surgical outcomes for patients with sarcopenia

21 Oct 2025

Ensitrelvir a viable alternative to available antivirals for COVID-19

21 Oct 2025 by

The investigational oral antiviral ensitrelvir shows potent antiviral activity in COVID-19, although its effect is slightly weaker than that of ritonavir-boosted nirmatrelvir, according to the ongoing, phase II, randomized controlled, adaptive pharmacometric platform PLATCOV trial.

Ensitrelvir a viable alternative to available antivirals for COVID-19

21 Oct 2025

Early IL-17 inhibitor use tied to quick response in psoriasis

21 Oct 2025

Early treatment with interleukin (IL)-17 inhibitors accelerates response and fosters disease modification in patients with psoriasis, reveals a study.

Early IL-17 inhibitor use tied to quick response in psoriasis

21 Oct 2025

Volar locking plating slightly improves wrist function in older adults with DRF

21 Oct 2025 by

The use of volar locking plating (VLP) for the operative treatment of primarily malaligned distal radius fracture (DRF) results in small improvements in wrist function at 12 months among older adults with DRF, reports a recent study.

Volar locking plating slightly improves wrist function in older adults with DRF

21 Oct 2025

Clinical practice attrition rates up since 2013: study

21 Oct 2025

Physician attrition from clinical practice across specialties has increased since 2013, according to a US study, noting specific patient and physician characteristics associated with a higher risk for attrition.

Clinical practice attrition rates up since 2013: study

21 Oct 2025

One in 10 hospitalized RSV patients has a concurrent acute CV event

21 Oct 2025 by

In a large cross-sectional study evaluating individuals hospitalized for respiratory syncytial virus (RSV), influenza, and COVID-19, one in 10 patients hospitalized for RSV had a concurrent acute cardiovascular (CV) event, and the odds of cardiac events were substantially higher in RSV vs COVID-19 hospitalizations.

One in 10 hospitalized RSV patients has a concurrent acute CV event

21 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

CORE model outperforms FIB-4 in predicting liver-related outcomes

CORE model outperforms FIB-4 in predicting liver-related outcomes

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

Even low alcohol intake detrimental to East Asian men with MASLD

Even low alcohol intake detrimental to East Asian men with MASLD

Prehabilitation improves surgical outcomes for patients with sarcopenia

Prehabilitation improves surgical outcomes for patients with sarcopenia

Ensitrelvir a viable alternative to available antivirals for COVID-19

Ensitrelvir a viable alternative to available antivirals for COVID-19

Early IL-17 inhibitor use tied to quick response in psoriasis

Early IL-17 inhibitor use tied to quick response in psoriasis

Volar locking plating slightly improves wrist function in older adults with DRF

Volar locking plating slightly improves wrist function in older adults with DRF

Clinical practice attrition rates up since 2013: study

Clinical practice attrition rates up since 2013: study

One in 10 hospitalized RSV patients has a concurrent acute CV event

One in 10 hospitalized RSV patients has a concurrent acute CV event